Pharmacokinetics, pharmacodynamics and clinical use of valganciclovir in newborns with symptomatic congenital cytomegalovirus infection

Current Drug Metabolism

Volumn 14, Issue 2, 2013, Pages 208-215

  Stronati, Mauro ^a   Lombardi, Giuseppina ^a   Garofoli, Francesca ^a   Villani, Paola ^a   Regazzi, Mario ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Clinical use; Congenital cytomegalovirus infection; Newborn; Pharmacodynamics; Pharmacokinetics; Valganciclovir

Indexed keywords

ABACAVIR; AMPHOTERICIN; BETA LACTAM ANTIBIOTIC; COTRIMOXAZOLE; DAPSONE; DIDANOSINE; DNA POLYMERASE; DOXORUBICIN; EMTRICITABINE; FLUCYTOSINE; LAMIVUDINE; PENTAMIDINE; VALGANCICLOVIR; VINBLASTINE; VINCRISTINE; ZIDOVUDINE;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONCENTRATION RESPONSE; CYTOMEGALOVIRUS INFECTION; DNA SYNTHESIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME PHOSPHORYLATION; EPSTEIN BARR VIRUS; FOLLOW UP; GASTROINTESTINAL TRACT; HEARING IMPAIRMENT; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HOSPITAL INFECTION; HUMAN; HYPERBILIRUBINEMIA; INFECTION RISK; INTESTINE WALL; LONG TERM CARE; NATIONAL HEALTH SERVICE; NEUTROPHIL COUNT; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; VARICELLA ZOSTER VIRUS;

EID: 84875307891     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200211314020009     Document Type: Article

References (50)

1. Dollard, S.C.; Grosse, S.D.; Ross, D.S. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Re. Med. Virol., 2007, 17, 355-363. (Pubitemid 47425872)
2. Michaels, M.G. Treatment of congenital cytomegalovirus: where are we now? Expert. Rev. Anti Infect. Ther., 2007, 5 (3), 441-448. (Pubitemid 47050165)
3. Schleiss, M.R. Congenital Cytomegalovirus infection: update on management strategies. Curr. Treat. Options Neurol., 2008, 10, 186-192.
4. Adler, S.P.; Nigro, G.; Pereira, L. Recent advances in the prevention and treatment of congenital cytomegalovirus infections. Semin. Perinatol., 2007, 31, 10-18. (Pubitemid 46273658)
5. Kenneson, A.; Cannon, M.J. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev. Med. Virol., 2007, 17, 253-276. (Pubitemid 47066638)
6. Malm, G.; Engman, M.L. Congenital citomegalovirus infections. Semin. Fetal Neonatal Med., 2007, 12, 154-159.
7. Barbi M.; Binda, S.; Caroppo, S.; Calvario, A.; Germinario, C.; Bozzi, A.; Tanzi, M.L.; Veronesi, L.; Mura, I.; Piana, A.; Solinas, G.; Pugni, L.; Bevilaqua, G.; Mosca, F.M. Multicity Italian Study of congenital cytomegalovirus infection. Pediatr. Infect. Dis. J., 2006, 25, 156-159. (Pubitemid 43208571)
8. Boppana, S.B.; Fowler, K.B.; Pass, R.F.; Rivera, L.B.; Russell, M.B.A.; Bradford, D.; Lakeman, F.D.; Britt, W.J. Congenital cy tomegalovirus infection: association between virus burden in infancy and hearing loss. J. Pediatr., 2005, 146, 817-823. (Pubitemid 40840605)
9. Oliver, S.E.; Cloud, G.A.; Sánchez, P.J.; Demmler, G.J.; Dankner, W.; Shelton, M.; Jacobs, R.F.; Vaudry, W.; Pass, R.F.; Soong, S.J.; Whitley, R.J.; Kimberlin, D.W. National Institute of Allergy, Infectious Diseases Collaborative Antiviral Study Group. Neurodevelopmental outcomes following GCV therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. J. Clin. Virol., 2009, 46(S4), S22-26.
10. Rivera, L.B.; Boppana, S.B.; Fowler, K.B.; Britt, W.J.; Stagno, S.; Pass, R.F. Predictor of hearing loss in children with symptomatic congenital cytomegalovirus infection. Pediatrics, 2002, 110(4), 762-767.
11. Nassetta, L.; Kimberlin, D.; Whitley R.J. Treatment of congenital cytomegalovirus infection: implications for future strategies. J. Antimicrob. Chemother. Antiviral, 2009, 63, 862-867.
12. Coll, O.; Benoist, G.; Ville, Y.; Weisman, L.E.; Botet, F.; Anceschi, M.M.; Greenough, A.; Gibbs, R.S.; Carbonell-Estrany, X. Guidelines on CMV congenital infection. J. Perinat. Med., 2009, 37(5), 433-45.
13. Marshall, B.C.; Koch, W.C. Antivirals for cytomegalovirus infection in neonates and infants. Focus on pharmacokinetics, formulations, dosing and adverse events. Pediatr. Drugs, 2009, 11(5), 309-321.
14. Available from: www.rocheusa.com/products/valcyte/pi.htlm
15. Curran, M.; Noble, S. Valaganciclovir. Drugs, 2001, 61(8), 1145-150.
16. Ganciclovir and valganciclovir. Drug Facts and Comparisons 4.0. Efacts [online]. 2009. Available from Wolters Kluwer Health, Inc. (accessed 7/14/09).
17. Razonable, R.R.; Paya, C.V. V-GCV for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. Expert. Rev. Anti Infect. Ther., 2004, 2(1), 27-41.
18. Zhang, D.; Lapeyraque, A.L.; Popon, M.; Loirat, C.; Jacqz-Aigrain, E. Pharmacokinetics of gangiclovir in pediatric renal transplant patients. Pediatr. Nephrol., 2003, 18(9), 943-948. (Pubitemid 37121631)
19. Trang, J.M.; Kidd, L.; Gruber, W.; Storch, G.; Demmler, G.; Jacobs, R.; Dankner, W.; Starr, S.; Pass, R.; Stagno, S. Linear single-dose pharmacokinetics of GCV in newborns with congenital cytomegalovirus infections. Clin. Pharmacol. Ther., 1993, 53,15-21. (Pubitemid 23036683)
20. Anderson, R.D.; Griffy, K.G.; Jung, D.; Dorr, A.; Hulse, J.D.; Smith, R.B. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus-and cytomegalovirus-seropositive patients. Clin. Ther., 1995, 17, 425-432.
21. Burri, M.; Wiltshire, H.; Kahlert, C.; Wouters, G.; Rudin, C. Oral V-GCV in children: single dose pharmacokinetics in a six-year-old girl. Pediatr. Infect. Dis. J., 2004, 23, 263-266. (Pubitemid 38332656)
22. Galli, L.; Novelli, A.; Chiappini, E.; Gervaso, P.; Casstte, M.I.; Fallani, S.; De Martino, M. V-GCV for congenital CMV infection: a pilot study on plasma concentration in newborns and infants. Ped. Infect. Dis. J., 2007, 26, 451-453. (Pubitemid 46789332)
23. Meine Jansen, C.F.; Toet, M.C.; Rademaker, C.M.A.; Ververs, T.F.F; Gerards, L.J.; Van Loon, A.M. Treatment of symptomatic congenital cytomegalovirus infection with V-GCV. J. Perinat. Med., 2005, 33, 364-366. (Pubitemid 41205874)
24. Acosta, E.P.; Brundage, R.C.; King, J.R.; Sánchez, P.J.; Sood, S.; Agrawal, V.; Homans, J.; Jacobs, R.F.; Lang, D.; Romero, J.R.; Griffin, J.; Cloud, G.; Whitley, R.; Kimberlin, D.W. GCV population pharmacokinetics in neonates following intravenous administration of GCV and oral administration of liquid V-GCV formulation. Clin. Pharmacol. Ther ., 2007,81, 867-872. (Pubitemid 46788295)
25. Czock, D.; Scholle, C.; Rasche, F.M.; Schaarschmidt, D.; Keller, F. Pharmacokinetics of V-GCV and GCV in renal impairment. Clin. Pharmacol. Ther., 2002, 72,142-150. (Pubitemid 35034492)
26. Kimberlin, D.W.; Acosta, E.P.; Sanchez, P.J.; Sood, S.; Agrawal, V.; Homans, J.; Jacobs, R.F.; Lang, D.; Romero, J.R.; Griffin, J.; Cloud, G.A.; Lakeman, F.D.; Whitley, R.J. Pharmacokinetic and Pharmacodynamic assessment of oral V-GCV in the treatment of symptomatic congenital cytomegalovirus disease. J. Infect. Dis., 2008, 197, 836-845. (Pubitemid 351417006)
27. Muller, A.; Eis-Hubinger, A.M.; Brandhorst, G.; Heep, A.; Bartmann, P.; Franz, A.R.Oral V-GCV for symptomatic congenital cytomegalovirus infection in an extremely low birth weight infant. J. Perinatol., 2008, 28, 74-76.
28. Hilgendorff, A.; Daiminger, A.; Dangel, V.; Kreuder, J.; Geidel, C.; Reiss, I.; Enders, G. Oral V-GCV treatment in a CMV congenital infected infant with sensorineural hearing loss (SNHL) first detected at 4 months of age. Klin. Padiatr., 2009, 221(7), 448-9
29. Lombardi, G.; Garofoli, F.; Villani, P.; Tizzoni, M.; Angelini, M.; Cusato, M.; Bollani, L.; De Silvestri, A.; Regazzi, M.; Stronati, M. Oral V-GCV treatment in newborns with symptomatic congenital cytomegalovirus infection. Eur. J. Clin. Microbiol. Infect. Dis., 2009, 28, 1465-1470.
30. Dantzig, A. H. Oral absorption of-lactams by intestinal peptide transport proteins. Adv. Drug Deliv. Rev., 1997, 23, 63-76. (Pubitemid 27046994)
31. Rubio-Aliaga, I.; Daniel, H. Mammalian peptide transporters as targets for drug delivery. Trends Pharmacol. Sci., 2002, 23, 434440.
32. Herrera-Ruiz, D.; Knipp, G. T. Current perspectives on established and putative mammalian oligopeptide transporters. J. Pharm. Sci., 2003, 92, 691-714. (Pubitemid 36396989)
33. Sugawara, M.; Huang, W.; Fei, Y.; Leibach, F.H.,; Ganapathy, V.; Ganaparhy, M.E. Transport of V-GCV, a GCV prodrug, via peptide transporters PEPT1 and PEPT2. J. Pharm. Sci., 2000, 89(6), 781-789.
34. Shen, H.; Smith, D.E.; Brosious, F.C. III. Developmental expression of PEPT1 and PEPT2 in rat small intestine, colon, and kidney. Pediatr. Res., 2001, 49, 789-795. (Pubitemid 32522055)
35. Nielsen, C.U.; Brodin, B. Di/tri peptide transporters as drug delivery targets: regulation of transport under physiological and pathophysiological conditions. Curr. Drug Targets, 2003, 4, 373-388. (Pubitemid 36758317)
36. Available from: http://www.drugs.com/drug-interactions/valganciclovir, valcyte.html
37. Available from: http://www. merckmanuals.com/professional/lexicomp/ valganciclovir.html
38. Whitley, R.J.; Cloud, G.; Gruber, W. GCV treatment of symptomatic congenital cytomegalovirus infections : results of a phase II study. J. Infect. Dis., 1997, 175, 1080-1086. (Pubitemid 27176494)
39. Kimberlin, D.W.; Lin, C.Y.; Sanchez, P.; Demmler, G.J.; Dankner, W.; Shelton, M.; Jacobs, R.F.; Vaudry, W.; Pass, R.F.; Kiell, J.M.; Soong, S.J.; Whitley, R.J. Effect of GCV therapy on hearing in symptomatic congenital Cytomegalovirus disease involving the central nervous system: a randomised, controlled trial. J. Pediatr., 2003, 143, 16-25. (Pubitemid 36928564)
40. Buonuomo, P.S.; Maurizi, P.; Valentini, P.; Mastrangelo, S.; Lazzareschi, I.; Ridola, V.; Riccardi, R. Successful treatment with oral V-GCV in immunocompetent infant with gastrointestinal manifestations of cytomegalovirus infection. J. Perinatol., 2006, 26, 648-649. (Pubitemid 44489572)
41. Schulzke, S.; Buhrer, C. V-GCV for treatment of congenital Cytomegalovirus infections. Eur. J. Pediatr., 2006, 165, 575-576. (Pubitemid 43989420)
42. Lanari, M.; Lazzarotto, T.; Venturi, V.; Papa, I.; Gabrielli, L.; Guerra, B.; Landini, M.P.; Faldella,G. Neonatal Cytomegalovirus blood load and risk of sequelae in symptomatic and asymptomatic congenitally infected newborns. Pediatrics, 2006, 117, 76-81.
43. Pass, R.F. Congenital cytomegalovirus infection and hearing loss. Herpes, 2005, 12, 50-55. (Pubitemid 41512784)
44. Baquero-Artigao, F.; Romero Gomez, M.P. Tratamiento prolongado con V-GCV en un lactante con infection congenita por citomegalovirus. An. Pediatr. (Barc), 2009, 70, 578-581.
45. Amir, J.; Wolf, D.G.; Levy, I. Treatment of symptomatic congenital cytomegalovirus infection with intravenous GCV followed by long-term oral V-GCV. Eur. J. Pediatr., 2010, 169, 1061-1067.
46. Baquero-Artigao, F.; Romero, M.; del Rosal, T.; Cernada, M.; Fortuny, C.; Moreno, D.; Saavedra, J.; Bringué, X.; Reyes, A.; Vilas, J.; Frick, M.A.; Cilleruelo, M.J.; Rojo, P.; Goncé, A.; Colino, E.; Ciria, L. Treatment of congenital symptomatic cytomegalovirus (CMV) infection with central nervous system (CNS) involvement with oral V-GCV (VGV) Proceedings Cytomegalovirus Conference Paris, Farance, September, 23-25, 2010.
47. Shoji, K.; Ito, N.; Inoue, N.; Adachi, S.; Fujimaru, T.; Nakamura, T.; Nishina, S.; Azuma, N.; Saitoh, A. Is a 6-week course of GCV therapy effective for chorioretinitis in infants with congenital cytomegalovirus (CMV) infection? J. Pediatr., 2010, 157, 331-333.
48. Lombardi, G.; Garofoli, F.; Angelini, M.; Maragliano, R.; Stronati, M. Oral V-GCV therapy in a 6-month old infant with congenital cytomegalovirus (CMV) infection and late hearing loss. Proceedings Cytomegalovirus Conference Paris, France, September, 23-25, 2010.
49. Gandhi, R.S.; Fernandez-Alvarez, J.R.; Rabe, H. Management of congenital cytomegalovirus infection: an evidence-based approch. Acta Ped., 2010, 99, 509-518.
50. Dahle, A.J.; Fowler, K.B.; Wright, J.D.; Boppana, S.B.; Britt, W.J.; Pass, R.F. Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus. J.Am. Acad. Audiol., 2000, 11(5), 283-290. (Pubitemid 30415997)